FIGURE 5.
hSERT C109A/G338C is accessible to MTSEA-biotin and capable of binding 5-HT. A, total [3H]citalopram binding of hSERT C109A/G338C and C109A/G342C, expressed as a percentage of hSERT C109A is shown. n.s., not significant. B, the ability of the hSERT C109A/G338C mutant to bind 5-HT was assessed by 5-HT competition of [3H]citalopram binding. ■, hSERT C109A; ▴, hSERT C109A/G338C. Bi, accessibility of hSERT C109A/G338C was assessed by application of 1 mm MTSEA-biotin in the presence and absence of 50 μm 5-HT and a subsequent Western blot using hSERT monoclonal antibody ST51–2 (see “Experimental Procedures”).